Some people who enter the biotech world have come from big pharma companies, and bring with them the kind of approaches that big pharma takes to clinical operations.

For example, many people who find themselves in charge of setting up trials for a biotech will reach out to the large CRO companies they’ve previously dealt with.

Which is fine as far as it goes, but I think sometimes people who switch from a big pharma to a smaller organization kind of fall into doing things the way they used to, rather than grasping the opportunity to do things differently.

A biotech or newer pharma company that doesn’t yet have a product in the market should really be able to capitalize on its position by throwing off the shackles of the preferred supplier list and identifying solutions that are more in line with the specific requirements they need for their current situation.